Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials

Fig. 3

Proportions of patients reporting improvements from baseline ≥ MCID in PROs to month 12. Proportions of patients reporting LS mean change from baseline ≥ MCID in a FACIT-F total score and b–i SF-36 domain scores, to month 12 across treatment groupsa pooled from Phase 3 ORAL Scan, ORAL Standard, and ORAL Sync study datasets (full analysis set). aAll treatments were administered in combination with background conventional synthetic disease-modifying antirheumatic drugs. * p < 0.05, ** p < 0.01, and *** p < 0.001 for tofacitinib and adalimumab vs placebo; p < 0.05 and †† p < 0.01 for tofacitinib vs adalimumab. ADA, adalimumab; BID, twice daily; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; MCID, minimum clinically important difference; PRO, patient-reported outcome; Q2W, once every 2 weeks; SE, standard error; SF-36, Short Form-36 Health Survey

Back to article page